Probabilistic Sensitivity Analysis in Cost-Effectiveness Models: Determining Model Convergence in Cohort Models. by Hatswell, Anthony J et al.
LSHTM Research Online
Hatswell, Anthony J; Bullement, Ash; Briggs, Andrew; Paulden, Mike; Stevenson, Matthew D;
(2018) Probabilistic Sensitivity Analysis in Cost-Effectiveness Models: Determining Model Conver-
gence in Cohort Models. PHARMACOECONOMICS, 36 (12). pp. 1421-1426. ISSN 1170-7690 DOI:
https://doi.org/10.1007/s40273-018-0697-3
Downloaded from: http://researchonline.lshtm.ac.uk/id/eprint/4654638/
DOI: https://doi.org/10.1007/s40273-018-0697-3
Usage Guidelines:
Please refer to usage guidelines at https://researchonline.lshtm.ac.uk/policies.html or alternatively
contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by-nc-nd/2.5/
https://researchonline.lshtm.ac.uk
Probabilistic sensitivity analysis in cost-effectiveness models; 
Determining model convergence in cohort models 
Anthony J. Hatswell1,2, Ash Bullement3, Andrew Briggs4, Mike Paulden5, Matt Stevenson6 
1. University College London, London, UK 
2. Delta Hat Limited, Nottingham, UK 
3. BresMed Health Solutions, Sheffield, UK 
4. University of Glasgow, Glasgow, UK 
5. University of Alberta, Edmonton, Canada 
6. University of Sheffield, Sheffield, UK 
 
Key words: cost-utility; health technology assessment; economic modelling; pharmacoeconomics 
 
Abstract  
Probabilistic sensitivity analysis (PSA) demonstrates the parameter uncertainty in a decision 
problem. The technique involves sampling parameters from their respective distributions (rather 
than simply using mean/median parameter values). Guidance in the literature, and from HTA bodies, 
on the number of simulations that should be performed suggests a  ‘sufficient number ?, or until 
 ‘convergence ? which is seldom defined. The objective of this tutorial is to describe possible 
outcomes from PSA, discuss appropriate levels of accuracy, and present guidance by which an 
analyst can determine if a sufficient number of simulations have been conducted, such that results 
are considered to have converged. The proposed approach considers the variance of the outcomes 
of interest in cost-effectiveness analysis as a function of the number of simulations. A worked 
example of the technique is presented using results from a published model, with recommendations 
made on best practice. While the technique presented remains essentially arbitrary, it does give a 
mechanism for assessing the level of simulation error and thus represents an advance over current 
practice of a round number of simulations with no assessment of model convergence. 
  
Key points for decision makers 
x An arbitrary number of probabilistic simulations may lead to unacceptable variability in 
results by chance alone  ? known as Monte Carlo error 
x There are a number of techniques by which model convergence can be assessed, our 
preferred being the running of the model until the 95% confidence interval for the 
incremental net monetary benefit does not include zero 
x For convenience, we have made available for download a worked example of how 
convergence may be demonstrated in probabilistic analysis 
1. Probabilistic sensitivity analysis in health economics 
Probabilistic sensitivity analysis (PSA) is a method for accounting for parameter uncertainty in cost-
effectiveness models. A distribution is assigned to each parameter, reflecting uncertainty in the true 
value, accounting where possible for the correlation between parameters. Samples are then 
repeatedly drawn from each distribution and used as model inputs. Each unique set of inputs (a 
ƐŝŶŐůĞ ‘ƐŝŵƵůĂƚŝŽŶ ǀĞĐƚŽƌ ?) results in a unique set of model outputs. Considering the results of many 
simulations allows for estimation of the expected (mean) model outputs and the uncertainty around 
these outputs [1,2].  
PSA is mandated by many health technology assessment (HTA) agencies internationally, including 
ƚŚĞh< ?ƐEĂƚŝŽŶĂů/ŶƐƚŝƚƵƚĞĨŽƌ,ĞĂůƚŚĂŶĚĂƌĞǆĐĞůůĞŶĐĞ ?E/) and the Canadian Agency for Drugs 
and Technologies in Health (CADTH) [3,4]. It is also recommended in guidelines published by the 
International Society for Pharmacoeconomics and Outcomes Research (ISPOR), and the Society for 
Medical Decision Making (SMDM) [5]. The reason for this requirement is in non-linear models, 
results based only on a fixed selection of input values will be biased. Common reasons for this are 
the use of median values where the median value does not equate to the mean value in the 
underlying distribution (such as a lognormal distribution) and where the combinations of changing 
parameters alter the number of patients simulated to experience health states associated with large 
costs utility impacts . Only through probabilistic analysis can the true results of non-linear models be 
identified. 
To illustrate the importance of using probabilistic analysis, a PSA was conducted using 250,000 
simulations in a published model [6]  ? this large number is assumed to give close approximations of 
 ‘ƚƌƵĞ ? Incremental Cost Effectiveness Ratio (ICER). Whilst the deterministic ICER was £25,961, the 
probabilistic estimate was £20,684 showing the difference that can occur between the two in non-
linear models. This was followed by a series of 20 additional PSAs where for each of this series the 
mean ICER was calculated separately over simulations 1 to n, for n = 1 to 10,000, allowing for 
consideration of change in the mean as the number of simulations increases. As the number of 
simulations increases, the range of the mean ICERs across the series of PSAs narrows (Figure 1). 
ĨƚĞƌ ? ? ? ? ?ƐŝŵƵůĂƚŝŽŶƐ ?ƚŚĞŵĞĂŶ/ZƐĐŽŶǀĞƌŐĞƚŽǁŝƚŚŝŶ ? ? ? ?ŽĨƚŚĞĞƐƚŝŵĂƚĞĚ ‘ƚƌƵĞ ?/ZŝŶĂůů
20 PSAs but only 12 of 20 had converged to within £250. Running more simulations 17 out of the 20 
had converged to within £250 at 5,000, with all 20 having done so by 10,000 simulations. 
Common presentations of PSA results include tabulation of mean model outputs and the probability 
that the intervention is cost-effective at plausible cost-effectiveness thresholds, scatterplots of 
simulations on the cost-effectiveness plane, cost-effectiveness acceptability curves (CEACs) and 
frontiers (CEAFs) [7,8]. These allow for consideration of the mean and distribution of model outputs 
[9] and may be used to inform value of information analysis [10]. 
Since PSA requires random sampling from distributions the parameter inputs will differ each time 
the PSA is repeated across equal numbers of simulations, such that the model outputs will also 
differ. In cohort models (the form of models we address in this tutorial), it follows that there are two 
uncertainties: the distribution of outputs across simulations within a PSA; and the difference 
between mean outputs across PSAs which reflects random noise (i.e. Monte Carlo error). The first 
type of uncertainty is what PSA aims to estimate, but the second type of uncertainty is undesirable.  
Fortunately, the greater the number of simulations conducted, the smaller the Monte Carlo error 
and if this error is sufficiently small, then ƚŚĞƌĞƐƵůƚƐĂƌĞƐĂŝĚƚŽŚĂǀĞ ‘ĐŽŶǀĞƌŐĞĚ ? as the error is 
considered inconsequential. 
Widespread convention in current practice is to conduct between 1,000 and 10,000 simulations, 
with no evidence presented on model convergence. Equally no specific guidance on convergence is 
currently provided by HTA agencies. Although conducting more simulations would generally reduce 
the Monte Carlo error, this increases the computational resources required and adds little value if 
convergence has already been reached. It follows that current practice is problematic: if too few 
simulations are conducted then the PSA results may incorporate substantial Monte Carlo error; but 
if too many simulations are conducted then the PSA is computationally inefficient. Without 
justification for the analysis performed, it is not possible to know where on this spectrum the 
analysis lies. 
The objective of this tutorial is to consider how model convergence can be considered in practice in 
cohort models (individual patient models are the topic of a separate literature). The topic is 
illustrated using the published example of chondrocyte implantation for cartilage damage of the 
knee [6]. 
2. Potential outcomes of interest 
In addition to the complexity of the economic model itself, the number of simulations required for 
convergence of any given model depends upon the outcomes of interest to the decision maker and 
the desired level of accuracy for each outcome. 
The most commonly considered model output is the ICER, typically the cost per quality-adjusted life 
year (QALY) gained. If the decision maker requires only an estimate of the mean ICER, the number of 
simulations should be just sufficient for this statistic to converge. Additional simulations may be 
required beyond the number required for the ICER statistic to converge if outputs other than the 
mean ICER are of interest to the decision maker [11,12]. For example, the decision maker may be 
interested in a confidence interval for the ICER estimate, the ƉƌŽďĂďŝůŝƚǇĂŶŝŶƚĞƌǀĞŶƚŝŽŶ ?ƐĐŽƐƚ-
effectiveness falls below a certain threshold, or the expected value of perfect information (EVPI) of 
an intervention. Alternatively it may be important that the estimated distributions of the model 
outputs are accurate between PSAs, and not merely the mean ICER alone. This may require 
additional simulations to ensure convergence towards the edges of each distribution which are 
inherently less stable than the mean. 
An alternative outcome is the incremental net benefit (INMB) statistic, a positive value of which 
signifies a technology is cost-effective [13,14]. Whilst ICERs may be more frequently used in decision 
making, the net-benefit statistic has a number of desirable properties compared to the ICER. Most 
importantly, the moments of its distribution are defined theoretically, such that it is possible to 
define a variance mathematically, and the assumption of a normal sampling distribution is 
reasonable under conditions imposed by the central limit theorem.  By contrast, the ICER, as a ratio 
of two random variables, does not have a mathematically tractable variance. 
For these reasons, we focus on net-benefit quantities in this tutorial in order to assess the 
convergence of important outcomes for the purposes of cost-effectiveness decision making, while 
recognising that the analyst may want to convert back to the use of the ICER when presenting the 
results of their cost-effectiveness analysis. 
3. Appropriate level of accuracy 
The desired level of accuracy for each outcome depends on the context. Models accompanying HTA 
submissions should exhibit a high degree of accuracy since they influence funding decisions. A high 
degree of accuracy is also desirable for a journal article that becomes a part of the scientific record. 
Conversely a low degree of accuracy may be sufficient for an early model during the development of 
a technology, or for a technology for which increased precision would not change the funding 
decision. For example, increased precision in a mean ICER estimated to be between £120,000 and 
£130,000 where the willingness to pay threshold (ʄ) is £30,000 per QALY would be superfluous to 
requirements.  
Ideally the decision maker would specify not only the outcomes of interest, but also the desired level 
of accuracy. This could be defined in terms of standard errors around the mean ICER, or absolute 
levels of accuracy e.g. ICERs to be reported within a tolerance of ±£500. A further request may also 
be for the probability an intervention is cost-effective, though in isolation these may be misleading, 
with funders typically preferring mean ICER [15]. For convenience the formulae for the confidence 
interval of the INMB and probability of being cost effective at a given threshold are given in Table 1. 
4. Defining convergence 
For a linear model, ƚŚĞĚĞƚĞƌŵŝŶŝƐƚŝĐŽƵƚƉƵƚƐƌĞƉƌĞƐĞŶƚƚŚĞ ‘ƚƌƵĞ ?ǀĂůƵĞƐĂŶĚthe mean outputs in a 
PSA will converge towards these values. It follows that the outputs of interest may be considered to 
have converged when they have stabilised (given the desired level of accuracy) to the respective 
deterministic outputs (i.e. the mean ICER has stabilised to within the specified accuracy of the 
deterministic ICER). 
For a non-linear model, the deterministic outputs will ƉƌŽǀŝĚĞďŝĂƐĞĚĞƐƚŝŵĂƚĞƐŽĨƚŚĞ ‘ƚƌƵĞ ?values. 
The  ‘ƚƌƵĞ ?values can only be estimated empirically: as the number of simulations increases, the 
mean outputs in the PSA will converge towards these  ‘true ? values (although by definition, these 
 ‘ƚƌƵĞ ?ǀĂůƵĞƐǁŝůůŶĞǀĞƌďĞŽďƐĞƌǀĞĚ ?. It follows that the outputs of interest may be considered to 
have converged when they have stabilised sufficiently close to the outputs that would be observed if 
an infinite number of simulations were to be performed. 
Regardless of the model type, each mean output in the PSA will fluctuate as the number of 
simulations increases, stabilising ĐůŽƐĞƚŽƚŚĞ ‘ƚƌƵĞ ?ǀĂůƵĞŽĨƚŚĞŽƵƚƉƵƚ ?ƵƌŝŶŐƚŚŝƐperiod of 
fluctuation, it is possible for a mean output to remain stable temporarily, or ƚŽůŝĞĐůŽƐĞƚŽƚŚĞ ‘ƚƌƵĞ ?
value by chance, only to diverge away as the number of simulations increases. To ensure 
convergence, it follows that it is not appropriate to halt a PSA immediately upon observing that a 
mean output appears stable; more robust methods are required. 
In determining convergence, the use of visual aids has been used previously in HTA submissions and 
journal publications, and can be an effective form of communicating how the level of uncertainty 
varies [16 ?18]. However, interpretation of visual aids is subjective and may imply stability (or 
instability) dependent on the scales of the plot chosen. 
Our suggested approach for determining when outputs have converged makes use of the INMB 
outcome by determining a confidence interval (CI) around the mean outcome. The CI around the 
point estimate of the INMB can then be translated to a CI around the point estimate of the ICER for 
presentation to a decision maker by instead of the INMB, calculating the ICER i.e. incremental cost 
divided by incremental QALY, as opposed to ʄ x incremental QALY  ? incremental cost. The choice of 
significance level will depend on the decision problem, however for simplicity we suggest this should 
be 5% or less as is current standard convention in the medical field. 
INMB is chosen specifically to avoid mathematical limitations of interpreting the uncertainty around 
the point estimate of a ratio, such as the ICER. The INMB is normally distributed (and therefore its 
variance is well defined) provided that the incremental costs and QALYs each follow a normal 
distribution (per the Central Limit Theorem, assuming a large [n>30] number of simulations). The 
variance around the point estimate of the ICER is undefined, and so convergence of the ICER is not 
determined directly. 
Based on this property of the INMB, the variance may be estimated within standard software such as 
Microsoft Excel®, and hence the standard error (SE) of the point estimate of the INMB may also be 
determined using the sample variance and the number of simulations. Thus, a CI around the point 
estimate of the INMB may be determined and is interpretable. 
For an adoption decision, if after a given number of simulations the CI of the INMB does not contain 
zero no further simulations are required  ? i.e. increased precision of the point estimate of the INMB 
would be very unlikely to change the decision made. Conversely, if the CI still contains zero after a 
given number of simulations, further simulations would be required to produce a CI that excludes 
zero. In the case of cohort models which have short computational times this is not anticipated to 
create a burden apart from a very rare situation where the true ICER was equal to ʄ. 
For decision makers, the ICER is most frequently used to present the results of cost-effectiveness 
analysis. As such, it is of interest to be able to present the uncertainty around the ICER itself  ? 
particularly for decision makers ǁŚĞƌĞʄŝƐĞŝƚŚĞƌƵŶĚĞĨŝŶĞĚ ?e.g. the Scottish Medicines Consortium 
[SMC]) or lies within a range (e.g. NICE) [4,19]. The value of ʄ at which the INMB is zero represents 
the point estimate of the ICER. The uncertainty in the INMB can be translated into the uncertainty in 
the ICER, by identifying the values of ʄat which the lower bound of the INMB is zero and the upper 
bound of the INMB is zero. These values may be found by trial and error or may be calculated using 
 ‘goal seek ? functionality within Microsoft Excel, or with similar mathematical programming functions 
in other software  ?ƐƵĐŚĂƐƚŚĞ ‘ůƉ^ŽůǀĞ ?Žƌ ‘ŶůŽƉƚƌ ?ƉĂĐŬĂŐĞƐŝŶƚŚĞƐƚĂƚŝƐƚŝĐ ůĂŶĂůǇƐŝƐƐŽĨƚǁĂƌĞR). 
 
5. Worked example 
For our proposed approach, we will consider the number of simulations required for the mean ICER 
to converge in our example model. The mean ICER should be calculated as the quotient of the mean 
incremental costs and QALYs over the number of simulations considered (i.e. not the mean of 
individually-calculated ICERs for each simulation). 
&ŽůůŽǁŝŶŐŽƵƌƌĞĐŽŵŵĞŶĚĞĚĂƉƉƌŽĂĐŚ ?ƚŚĞǀĂůƵĞŽĨʄŵĂǇďĞĚĞĨŝŶĞĚ ?ƐƐƵŵŝŶŐĂʄŽĨ ? ? ? ? ? ? ? ?and 
a significance level of 5%, the resultant point estimate and CI of the mean INMB achieved after 500 
simulations is -£120 (95% CI: -£687, £447). As this CI includes zero, the conclusion drawn is that a 
larger number of simulations are required. Increasing the number of simulations to 1,000 yields a 
result of -£426 (95% CI: -£825, -£27). As this CI no longer contains zero, 1,000 simulations may be 
considered sufficient in this example as the adoption decision would be unlikely to change should an 
increased number of simulations be performed. 
,ŽǁĞǀĞƌ ?ʄŵĂǇŶŽƚďĞĚĞĨŝŶĞĚ ?/ŶƚŚŝƐĐĂƐĞ ?ůĞƚƵƐĂƐƐƵŵĞƚŚĞĚĞĐŝƐŝŽŶŵĂŬĞƌŝƐŝŶƚĞƌĞƐƚĞĚŝŶ
obtaining an ICER within a maximum tolerance of ɸA?£500 in either direction. The associated point 
estimates and 95% CI around the ICER is £20,181 (£19,427, £20,943). Given the width of this CI is 
greater than £1,000, further iterations would be required. For 1,000 iterations, the results are 
£20,575 (£20,035, £21,140). This width is close to £1,000; but is not smaller and so an increased 
number of simulations are required. Using 1,500 simulations provides a result of £20,564 (£20,125, 
£21,027), and so with a width of less than £1,000 this number of simulations would be considered 
sufficient. 
If an appropriate ʄĂŶĚɸĂƌĞnot available from decision makers, a reasonable value should be made 
in relation to the decision problem. For example, if after 1,000 simulations the resultant ICER is 
 ? ? ? ? ? ? ? ?ĂŶĂƉƉƌŽƉƌŝĂƚĞĐŚŽŝĐĞŽĨɸŵĂǇďĞɸA?£500 in either direction; whereas if after 1,000 
simulations ƚŚĞƌĞƐƵůƚĂŶƚ/ZŝƐ ? ? ? ? ? ? ? ?ĂŶĂƉƉƌŽƉƌŝĂƚĞĐŚŽŝĐĞŽĨɸŵĂǇďĞɸA? ? ? ? ? ? ?ŝŶĞŝƚŚĞƌ
direction. Although crude, this approach allows for consideration of the Monte Carlo error and 
provides guidance as to the number of simulations required for convergence.  
Whilst these examples of ɸ may appear arbitrary, it represents an advance over current practice, 
under which an arbitrary number of simulations is conducted with no consideration as to whether 
convergence has been reached. When specifying ɸ we are able to have confidence the true value is 
in the region of ɸ, as opposed to running an arbitrary number of simulations when we are not able to 
conclude to what degree of accuracy the model has converged. 
 
6. Acknowledgement of other methods 
Several other methods have also been used to define convergence. The methods we believe to be 
most relevant are the jackknife and Taylor series estimates of the standard error around the point 
estimates of the ICER. The jackknife was proposed by Efron [20] to give an approximate mean and 
variance of a parameter of interest. The Taylor series is statistically more efficient than the jackknife 
[21], and is an expansion of a function in to an infinite sum of its terms  ? by taking the first n terms 
of a series, it then uses a derivative of this function to determine the likely form from which minima 
and maxima can be estimated.  
Both the jackknife and Taylor series methods make the assumption that the SE of the point estimate 
of the ICER may be calculated, assuming normality in the distribution of the mean ICER and 
therefore disregarding the skewness of the distribution. For this reason, these methods are not 
recommended in case either component of the ICER approaches zero where this assumption of 
normality will not hold. If applied to the INMB, these approaches provide near-identical results to 
the assumption of normality (our proposed method) in a simulation study (data not shown). 
There may be a situation that calls for very accurate estimates of model results (e.g. for a model with 
ŚŝŐŚďƵĚŐĞƚĂƌǇŝŵƉĂĐƚǁŝƚŚĂŶ/ZůǇŝŶŐĐůŽƐĞƚŽʄ ?. In these rare cases the use of a large number of 
simulations presents a valid (although crude and computationally burdensome) approach to defining 
convergence. Importantly, the timeliness of producing results in general is paramount in decision 
making, leading to us not recommending this approach as in many situations it would not be 
possible to undertake within a restricted timeframe. 
 
7. Recommendations 
In this tutorial we have considered the appropriate number of simulations to conduct in PSA. 
Current practice is to use an arbitrary number of simulations, regardless of the model ?Ɛ complexity  ? 
this  ‘one size fits all ? approach is not ideal and may result in substantial Monte Carlo error or wasted 
computational resources (and no possibility of determining which is the case). Using the 
recommended method highlighted in this tutorial, it is possible to consider the number of 
simulations required for the outcome of interest to converge to the desired degree of accuracy. 
Although our example focussed on the INMB and ICER, these methods generalise to other outcomes 
of interest. 
Due to differences in the complexity of models, it is not possible to recommend a specific number of 
simulations to be used in all circumstances. Furthermore, the outcomes of interest and accuracy 
required may (legitimately) vary between decision makers. Some decision makers may desire precise 
estimates of multiple model outputs, whereas others may only be interested in whether the mean 
ICER is above or below the threshold  ?ʄ ?. We therefore recommend that decision makers explicitly 
identify the outcome(s) of interest and the desired degree of accuracy where possible. In the 
absence of such guidance analysts should adopt a transparent and methodical approach to defining 
an appropriate level of convergence. This also applies to EVPI where guidance does exist on the most 
efficient techniques [22]. 
The method detailed in this tutorial provides a general guide to providing an informed 
demonstration of model convergence, via the use of a CI around the point estimate of the INMB or 
ICER. The method proposed exhibits clear advantages over other methods, through the avoidance of 
mathematical issues pertaining to the derivation of the variance of a ratio (which is undefined) or 
subjective interpretation of visual plots. Visual plots may serve as a useful complement to intuitively 
demonstrate convergence, as in Figure 1, but should not be relied upon alone. Depending on the 
decision problem, an increased level of precision (e.g. the use of a 99% CI) may be preferable. 
However, the derivation of a 99% CI around the mean ICER may be time-ĐŽŶƐƵŵŝŶŐŝĨƚŚĞ ‘ƚƌƵĞ ?/Z
ůŝĞƐĐůŽƐĞƚŽʄ and therefore ascertaining a CI with greater precision should be undertaken with 
caution. The reason for this is towards the edges of a distribution the uncertainly can be profound, 
with values highly unstable and by definition rarely sampled  ? ƚŚĞ ‘ĐŽƐƚ ?ŝŶĐŽŵƉƵƚŝŶŐƉŽǁĞƌƚŽ
obtain this range may be prohibitive. 
 
8. Conclusions 
The de facto standard of 1,000 to 10,000 simulations may be sufficient in some circumstances, this is 
not guaranteed; this is particularly the case where the distribution of an outcome is of interest to the 
decision maker, rather than simply the mean. Although modellers should be encouraged to choose 
an appropriate method for demonstration of convergence, in the majority of cases we expect the 
proposed approach will suffice. An Excel workbook with a worked example of our method for 
calculating the mean value can be freely downloaded at http://www.deltahat.co.uk/experience/psa 
The approach we propose does have limitations and remains, to some degree, arbitrary in its level of 
accuracy. More important than the exact method used however, is that the issue of convergence be 
considered in probabilistic analysis. Until this is widely done, there is the very real possibility of 
undiagnosed inaccuracy in results, which could in turn affect decision making. 
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Table 1: Confidence interval formulae for potential outcomes of interest 
Outcome of interest Confidence interval formula 
Incremental Net 
Monetary Benefit, 
INMB 
 
Probability of being 
cost-HIIHFWLYHJLYHQȜ 
 
QALY, Quality Adjusted Life Year; ʄ, Willingness to pay threshold, ɲ, confidence level divided by two 
  
Figure 1: Graphical plot of convergence for repeated runs of 10,000 simulations 
 
Key: ICER, incremental cost-effectiveness ratio; PSA, probabilistic sensitivity analysis. 
Notes: dŚĞ ‘ƚƌƵĞ ?/ZƌĞĨůĞĐƚƐƚŚĞŵĞĂŶ/ZŽďƚĂŝŶĞĚďǇĂW^ of 250,000 simulations. Each of the 
numbered PSAs represents a separate PSA run of up to 10,000 simulations, with the plot 
demonstrating the route to convergence as the number of simulations increases.  
 
